TrialJournal of neuro-oncology2026

Long-term outcomes after a randomized phase II trial of nerve growth factor eye drops for optic pathway gliomas: four-year follow-up findings in children.

Antonio Ruggiero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.